XenoPort Reports Second Quarter Financial Results – Marketwatch

Posted on August 15, 2011 by admin

XenoPort initiated a pivotal Phase 3 clinical trial of arbaclofen placarbil (AP) as a potential treatment of spasticity in multiple sclerosis (MS) patients. Assuming positive results, the pivotal trial, which is being conducted under a Special Protocol … Bing News – Full Story →

Share

Related posts:

  1. XenoPort Reports Third Quarter Financial Results – Yahoo Finance
  2. XenoPort (XNPT), FDA Agree on SPA for Pivotal XP19986 Phase 3 in MS Patients – StreetInsider.com
  3. Cytokinetics, Incorporated Reports Third Quarter 2010 Financial Results – msnbc.com
  4. Chelsea Therapeutics Reports Second Quarter 2011 Results – Yahoo Finance
  5. Cyclacel Pharmaceuticals to Announce Year End & Fourth Quarter 2010 Financial Results and Presentation at Upcoming Conference – msnbc.com
This entry was posted in Neuromuscular Disorders and tagged , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>